{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.5","upperLimit":"83.0","value":"72.9"},{"groupId":"OG001","lowerLimit":"36.1","upperLimit":"63.3","value":"50.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"The primary endpoint is to compare the two-year progression-free survival (PFS) of patients treated with the myeloablative consolidation treatment strategy of HDT/ASCT versus those treated with non-myeloablative consolidation chemotherapy with cytarabine and etoposide.\n\nPFS time = time from Registration to earliest date of Progression or Death due to any cause, censoring non-progressed and alive patients at the date of last disease status evaluation.\n\nResponse will be defined using the modified IPCG criteria. Progressive disease is defined as \\> 25% increase in contrast-enhancing CNS (brain and spine if latter abnormal at baseline) disease, appearance of any new, measurable (\\>/= 10mm) contrast-enhancing disease or recurrent or new ocular or CSF disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant.\n\n\\>\n\n\\> carmustine: Given IV\n\n\\>\n\n\\> thiotepa: Given IV\n\n\\>\n\n\\> stem cell transplant\n\n\\>\n\n\\> G-CSF","id":"OG000","title":"Arm I"},{"description":"Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy.\n\n\\>\n\n\\> cytarabine: Given IV\n\n\\>\n\n\\> etoposide: Given IV\n\n\\>\n\n\\> G-CSF","id":"OG001","title":"Arm II"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Progression Free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants w/out event"}